Metabolic mitigation of staphylococcus aureus vancomycin intermediate-level susceptibility

Stewart G. Gardner, Darrell D. Marshall, Robert S. Daum, Robert Powers, Greg A Somerville

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Staphylococcus aureus is a major human pathogen whose infections are increasingly difficult to treat due to increased antibiotic resistance, including resistance to vancomycin. Vancomycin-intermediate S. aureus (VISA) strains develop resistance to vancomycin through adaptive changes that are incompletely understood. Central to this adaptation are metabolic changes that permit growth in the presence of vancomycin. To define the metabolic changes associated with adaptive resistance to vancomycin in S. aureus, the metabolomes of a vancomycin-sensitive and VISA strain pair isolated from the same patient shortly after vancomycin therapy began and following vancomycin treatment failure were analyzed. The metabolic adaptations included increases in acetogenesis, carbon flow through the pentose phosphate pathway, wall teichoic acid and peptidoglycan precursor biosynthesis, purine biosynthesis, and decreased tricarboxylic acid (TCA) cycle activity. The significance of these metabolic pathways for vancomycin-intermediate susceptibility was determined by assessing the synergistic potential of human-use-approved inhibitors of these pathways in combination with vancomycin against VISA strains. Importantly, inhibitors of amino sugar and purine biosynthesis acted synergistically with vancomycin to kill a diverse set of VISA strains, suggesting that combinatorial therapy could augment the efficacy of vancomycin even in patients infected with VISA strains.

Original languageEnglish (US)
Article numbere01608
JournalAntimicrobial Agents and Chemotherapy
Volume62
Issue number1
DOIs
StatePublished - Jan 2018

Fingerprint

Vancomycin
Staphylococcus aureus
Vancomycin Resistance
Teichoic Acids
Amino Sugars
Pentose Phosphate Pathway
Citric Acid Cycle
Metabolome
Peptidoglycan
Microbial Drug Resistance
Metabolic Networks and Pathways
Treatment Failure
Carbon

Keywords

  • Metabolism
  • Physiology
  • Staphylococcus aureus
  • Vancomycin resistance

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Metabolic mitigation of staphylococcus aureus vancomycin intermediate-level susceptibility. / Gardner, Stewart G.; Marshall, Darrell D.; Daum, Robert S.; Powers, Robert; Somerville, Greg A.

In: Antimicrobial Agents and Chemotherapy, Vol. 62, No. 1, e01608, 01.2018.

Research output: Contribution to journalArticle

@article{19597817539b4202a5da58e03608b18c,
title = "Metabolic mitigation of staphylococcus aureus vancomycin intermediate-level susceptibility",
abstract = "Staphylococcus aureus is a major human pathogen whose infections are increasingly difficult to treat due to increased antibiotic resistance, including resistance to vancomycin. Vancomycin-intermediate S. aureus (VISA) strains develop resistance to vancomycin through adaptive changes that are incompletely understood. Central to this adaptation are metabolic changes that permit growth in the presence of vancomycin. To define the metabolic changes associated with adaptive resistance to vancomycin in S. aureus, the metabolomes of a vancomycin-sensitive and VISA strain pair isolated from the same patient shortly after vancomycin therapy began and following vancomycin treatment failure were analyzed. The metabolic adaptations included increases in acetogenesis, carbon flow through the pentose phosphate pathway, wall teichoic acid and peptidoglycan precursor biosynthesis, purine biosynthesis, and decreased tricarboxylic acid (TCA) cycle activity. The significance of these metabolic pathways for vancomycin-intermediate susceptibility was determined by assessing the synergistic potential of human-use-approved inhibitors of these pathways in combination with vancomycin against VISA strains. Importantly, inhibitors of amino sugar and purine biosynthesis acted synergistically with vancomycin to kill a diverse set of VISA strains, suggesting that combinatorial therapy could augment the efficacy of vancomycin even in patients infected with VISA strains.",
keywords = "Metabolism, Physiology, Staphylococcus aureus, Vancomycin resistance",
author = "Gardner, {Stewart G.} and Marshall, {Darrell D.} and Daum, {Robert S.} and Robert Powers and Somerville, {Greg A}",
year = "2018",
month = "1",
doi = "10.1128/AAC.01608-17",
language = "English (US)",
volume = "62",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Metabolic mitigation of staphylococcus aureus vancomycin intermediate-level susceptibility

AU - Gardner, Stewart G.

AU - Marshall, Darrell D.

AU - Daum, Robert S.

AU - Powers, Robert

AU - Somerville, Greg A

PY - 2018/1

Y1 - 2018/1

N2 - Staphylococcus aureus is a major human pathogen whose infections are increasingly difficult to treat due to increased antibiotic resistance, including resistance to vancomycin. Vancomycin-intermediate S. aureus (VISA) strains develop resistance to vancomycin through adaptive changes that are incompletely understood. Central to this adaptation are metabolic changes that permit growth in the presence of vancomycin. To define the metabolic changes associated with adaptive resistance to vancomycin in S. aureus, the metabolomes of a vancomycin-sensitive and VISA strain pair isolated from the same patient shortly after vancomycin therapy began and following vancomycin treatment failure were analyzed. The metabolic adaptations included increases in acetogenesis, carbon flow through the pentose phosphate pathway, wall teichoic acid and peptidoglycan precursor biosynthesis, purine biosynthesis, and decreased tricarboxylic acid (TCA) cycle activity. The significance of these metabolic pathways for vancomycin-intermediate susceptibility was determined by assessing the synergistic potential of human-use-approved inhibitors of these pathways in combination with vancomycin against VISA strains. Importantly, inhibitors of amino sugar and purine biosynthesis acted synergistically with vancomycin to kill a diverse set of VISA strains, suggesting that combinatorial therapy could augment the efficacy of vancomycin even in patients infected with VISA strains.

AB - Staphylococcus aureus is a major human pathogen whose infections are increasingly difficult to treat due to increased antibiotic resistance, including resistance to vancomycin. Vancomycin-intermediate S. aureus (VISA) strains develop resistance to vancomycin through adaptive changes that are incompletely understood. Central to this adaptation are metabolic changes that permit growth in the presence of vancomycin. To define the metabolic changes associated with adaptive resistance to vancomycin in S. aureus, the metabolomes of a vancomycin-sensitive and VISA strain pair isolated from the same patient shortly after vancomycin therapy began and following vancomycin treatment failure were analyzed. The metabolic adaptations included increases in acetogenesis, carbon flow through the pentose phosphate pathway, wall teichoic acid and peptidoglycan precursor biosynthesis, purine biosynthesis, and decreased tricarboxylic acid (TCA) cycle activity. The significance of these metabolic pathways for vancomycin-intermediate susceptibility was determined by assessing the synergistic potential of human-use-approved inhibitors of these pathways in combination with vancomycin against VISA strains. Importantly, inhibitors of amino sugar and purine biosynthesis acted synergistically with vancomycin to kill a diverse set of VISA strains, suggesting that combinatorial therapy could augment the efficacy of vancomycin even in patients infected with VISA strains.

KW - Metabolism

KW - Physiology

KW - Staphylococcus aureus

KW - Vancomycin resistance

UR - http://www.scopus.com/inward/record.url?scp=85039794764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039794764&partnerID=8YFLogxK

U2 - 10.1128/AAC.01608-17

DO - 10.1128/AAC.01608-17

M3 - Article

C2 - 29109158

AN - SCOPUS:85039794764

VL - 62

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 1

M1 - e01608

ER -